Background: Maternal infection with rubella in the first trimester of pregnancy can result in developmental abnormalities in fetus such as hearing loss, heart abnormalities, impaired vision, and mental retardation. Methods: This Multi-stage prospective/cross sectional study was carried out in three stages in three educational hospitals in Tehran (Rasoul akram, Akbar Abadi and Firoozabadi), during 2011-2012: In first stage, 186 infants at birth day. Rubella antibodies (IgG&IgM) in cord blood was evaluated by Eliza method. In second stage, 89 infants suspected INTRA UTERINE INFECTION and in third stage 165 infants with SNHL were selected . Age matched control group were selected and examined concurrently. Rubella antibodies (IgG&IgM) compared between cases and healthy matched infants. Results: In first stage, significant correlation was found between vaccination history and rubella immunization of mothers (P value = 0.001). None of those with a history of vaccination had positive IgM. In second stage, confirmed CRS (positive IgM) was found in 4.4% of total CRS suspected cases (5 /89). The positive RT–PCR detected in 1.5% of total CRS suspected cases (1/89). Except a positive correlation between abnormal neurologic findings and positive IgM in Confirmed CRS cases, other clinical findings were not related to serologic tests. In third stage, the highest frequency for Positive Rubella-IgM observed in the SNHL cases <1 year old (P-value = 0.14). Rubella-IgG was significantly higher in age group < 1 years (P-value = 0.001). There was no significant difference for Rubella-IgM (P-value = 0.6) between SNHL cases and controls but a significant (P-value = 0.000) difference was observed for Rubella-IgG which was more frequent in control group.Conclusion: Active CRS surveillance is recommended strongly even in country with full rubella vaccination. Without active CRS surveillance ;CRS especially, mild infection ( not classic form) such as IUGR(intrauterine growth retardation), hearing loss, heart abnormalities, impaired vision, and mental retardation even in developed country might be missed . The necessity to add a booster vaccine dose to the national vaccination program 8 years after the last vaccination should be evaluated if needed. In addition, follow-up of safety status and studies to evaluate the success of the program may be necessary and is recommended.